To hear about similar clinical trials, please enter your email below
Trial Title:
Role of Bronchoscope in Diagnosis of Lung Cancer
NCT ID:
NCT05992740
Condition:
Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Crossover Assignment
Intervention model description:
analytical cross sectional
Primary purpose:
Diagnostic
Masking:
Single (Participant)
Intervention:
Intervention type:
Device
Intervention name:
bronchoscope
Description:
bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
Arm group label:
bronchial brush
Arm group label:
bronchial wash group
Summary:
The study aims to compare the diagnostic yields of bronchial brushing performed before
and after forceps biopsy and bronchial wash performed before and after biopsy during
flexible bronchoscopy.
Detailed description:
Lung cancer is the most common cause of cancer-related mortality in both sexes in the
world. To treat the disease successfully, it should be diagnosed at the earliest possible
stage. Several studies have demonstrated that early detection, localization, and
aggressive treatment of lung cancer result in the 5-year survival rate of 70-80%.
Nowadays, bronchoscopy is an invaluable tool for diagnosis of lung cancer and various
diagnostic tools have been developed using flexible fiber-optic bronchoscopy (FOB).
Bronchoscopy, while essential for diagnosing and staging lung cancer, can give variable
diagnostic yields ranging from37-77%. One reason for this variability is limitations in
tissue sampling techniques, which can make it impossible to obtain the most
representative area of neoplastic tissue. Numerous basic diagnostic procedures using FB,
including bronchoalveolar lavage or washing, brushing, endobronchial or transbronchial
biopsy(TBB), and transbronchial needle aspiration, have been evaluated in various
combinations to improve the diagnostic yield of FB in patients with suspected lung
cancer. However, the optimum sequence of brushing, washing and biopsy samples for
diagnosing peripheral lung cancer is not clear and requires further study.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Patients in whom clinical findings, radiological examination suggested lung malignancy.
patients with chronic cough, hemoptysis and lymph node enlargement.
Exclusion Criteria:
patients with no evidence of malignancy.
Gender:
All
Minimum age:
18 Years
Maximum age:
90 Years
Healthy volunteers:
No
Start date:
October 1, 2023
Completion date:
October 2025
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05992740
